Drugs / PWT33597
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01407380 | Jun 2011 → Aug 2012 | cancer | Pathway Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PWT33597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01407380 ↗ |
| Known as | PWT33597 mesylate | “This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.” NCT01407380 ↗ |
| Route | Oral | “PWT33597 taken orally daily for 28 consecutive days in 28 day cycle” NCT01407380 ↗ |